The effect of daily intraperitoneal injection of Deferoxamine in an acute model of Cisplatin induced nephrotoxicity

The effect of daily intraperitoneal injection of Deferoxamine in an acute model of Cisplatin induced nephrotoxicity

Cisplatin is a major classical anticancer agents. However, cisplatin induced nephrotoxicity remains a major dose limiting side effect. Several studies has highlighted the role of catalytic iron content in several diseases including cispatin nephrotoxicity opening the doors for adding iron chelators...

Full description

Bibliographic Details
Main Authors:	Mohamed M Elmazar, Ebtehal El-Demerdash, Samar S Azab, Reem N Elnaga, Eman M Mantawy, Mai M Abdelmageed
Format:	Article
Language:	English
Published:	Ain Shams University 2020-12-01
Series:	Archives of Pharmaceutical Sciences Ain Shams University
Subjects:	cisplatin deferoxamine acute renal injury catalytic iron intraperitoneal chelation therapy
Online Access:	https://aps.journals.ekb.eg/article_135135.html

Similar Items

Assessment of nephrotoxicity associated with combined cisplatin and mitomycin C usage in laparoscopic hyperthermic intraperitoneal chemotherapy
by: Ravish Kapoor, et al.
Published: (2019-01-01)

The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity
by: Masanari Umemura, et al.
Published: (2017-08-01)

Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator
by: Denise Bellotti, et al.
Published: (2021-05-01)

Lens opacity as a serious side effect following chelation therapy in beta thalassemia: A comparison between deferoxamine and deferasirox; randomized double-blinded clinical trial
by: Mohammad Reza Golpayegani, et al.
Published: (2019-01-01)

Protective Effects of Deferoxamine on Vestibulotoxicity in Gentamicin-Induced Bilateral Vestibulopathy Rat Model
by: Hyo-Jung Kim, et al.
Published: (2021-03-01)

Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
by: V. G. Bespalov, et al.
Published: (2016-02-01)

Preparation and optimization of polymeric micelles as an oral drug delivery system for deferoxamine mesylate: in vitro and ex vivo studies
by: Anayatollah Salimi, et al.
Published: (2019-01-01)

Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
by: Wu-yun Wang, et al.
Published: (2021-01-01)

Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma
by: Megan Lander, et al.
Published: (2020-05-01)

Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer
by: Megan E. McDonald, et al.
Published: (2017-05-01)

A Novel Star Like Eight-Arm Polyethylene Glycol-Deferoxamine Conjugate for Iron Overload Therapy
by: Bohong Yu, et al.
Published: (2020-04-01)

A Theoretical Model for Intraperitoneal Delivery of Cisplatin and the Effect of Hyperthermia on Drug Penetration Distance
by: Ardith W. El-Kareh, et al.
Published: (2004-03-01)

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO)
by: Maria Lazaridou, et al.
Published: (2020-03-01)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes
by: Kontoghiorghe CN, et al.
Published: (2016-01-01)

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report
by: Clemens B. Tempfer, et al.
Published: (2014-12-01)

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients
by: Nargesbeygom Mirbehbahani, et al.
Published: (2015-01-01)

Intraperitoneal chemotherapy for peritoneal metastases using sustained release formula of cisplatin-incorporated gelatin hydrogel granules
by: Yamashita, Kota
Published: (2019)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
by: Shahla Ansari, et al.
Published: (2017-06-01)

Protective action of deferiprone and deferoxamine in erythrocytes isolated from patients with β-thalassemias Ação protetora de deferiprona e desferoxamina nos eritrócitos isolados de pacientes com β-talassemias
by: Alisson F. Santos, et al.
Published: (2009-01-01)

Cisplatin Induced Nephrotoxicity
by: Seyed Seifollah Beladi Mousavi, et al.
Published: (2014-02-01)

A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
by: Chui-ying Chan, et al.
Published: (2021-03-01)

Deferoxamine synergizes with transforming growth factor-β signaling in chondrogenesis
by: Zheng Huang, et al.
Published: (2017-08-01)

DEFEROXAMINE ACCELERATED HEALING IN OPEN EXCISION WOUND MODEL IN RATS
by: Mahendra Ram, et al.
Published: (2016-06-01)

Combination therapies in iron chelation
by: Raffaella Origa
Published: (2014-12-01)

Improving the functionality of infected, iron loaded mammalian cells through the use of DFO in an in vitro protocol
Published: (2009)

Improving adherence with deferoxamine regimen in thalassemia major using education
by: Gholamreza Pouladfar, et al.
Published: (2006-02-01)

Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy
by: Matilde Zaballos, et al.
Published: (2021-01-01)

Iron Chelator Drugs in Transfusion Dependent Thalassemia: a Review
by: M Hashemieh
Published: (2020-08-01)

Interactions of Alginate-Deferoxamine Conjugates With Blood Components and Their Antioxidation in the Hemoglobin Oxidation Model
by: Tong Sun, et al.
Published: (2020-02-01)

Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature
by: Constantine D. Georgakopoulos, et al.
Published: (2018-09-01)

Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload
by: Wu D, et al.
Published: (2018-05-01)

Effects of iron chelating agent on Schistosoma mansoni infected murine model
by: Noha H. Abdelgelil, et al.
Published: (2019-01-01)

Urinary iron excretion induced by intravenous infusion of deferoxamine in ß-thalassemia homozygous patients
by: Boturão-Neto E., et al.
Published: (2002-01-01)

Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease
by: Jacob Kosyakovsky, et al.
Published: (2021-01-01)

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
by: Alpendurada Francisco, et al.
Published: (2012-01-01)

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia
by: Hayder M Al-Kuraishy, et al.
Published: (2017-01-01)

Comparison of Deferoxamine, Activated Charcoal, and Vitamin C in Changing the Serum Level of Fe in Iron Overloaded Rats
by: Reza Ghafari, et al.
Published: (2014-02-01)

Deferoxamine Reduces Inflammation and Osteoclastogenesis in Avulsed Teeth
by: Ko Eun Lee, et al.
Published: (2021-07-01)

Iron chelating agents for iron overload diseases
by: Guido Crisponi, et al.
Published: (2014-09-01)

Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
by: Nuzzi R, et al.
Published: (2021-05-01)